An interventional study of Fast discharge strategy in Acute Myocardial Infarction (AMI), sponsored by Medical University Innsbruck. Recruiting at 8 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-16.
Sponsored by Medical University Innsbruck · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies in Myocardial Infarction with a site in Austria — 8 open to participants now, 12 under way, 5 of them phase 3. Myocardial Infarction · Austria.
Among the 48 studies in Myocardial Infarction with a site in Austria, this one is the 16th largest by planned enrollment of the 35 interventional ones that give a count, is one of 3 that started in 2024, is one of 10 with no phase, reaches primary completion later than 10 of the 11 other live ones, and was the 44th registered.
2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.
Browse Myocardial Infarction studies →8 of the 48 studies in Myocardial Infarction with a site in Austria are open now. Recruiting first, the newest first:
Medical University of Vienna · Sites in Austria
Ages 18+
Novo Nordisk A/S · Sites in Austria, Denmark, Italy and 3 more countries
Ages 18+
CSL Behring · Sites in Austria, United States, Argentina and 32 more countries
Ages 18+
Charite University, Berlin, Germany · Sites in Austria, Belgium, Czechia and 10 more countries
Ages 18+
Medical University of Graz · Sites in Austria
Ages 19–90 · Healthy volunteers
A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →
Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 16 · Phase 4 5
First in 2001; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,070 is above the median of 150 across 1,317 interventional studies indexed under Myocardial Infarction.
Median enrollment 1,875 across the 35 interventional studies, 718 across the 13 observational. Of the 34 that completed or were terminated, 9 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 48 have an industry lead sponsor. The 10 most frequent:
Medical University Innsbruck is the lead sponsor of 187 studies on the registry; 48 are open to participants now.
Medical University Innsbruck has 1 study filed under Myocardial Infarction — fewer than ten, so there is no comparison to draw.
4 of the studies in Myocardial Infarction with a site in Austria that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04957719Phase 3Viatris Innovation GmbHSelatogrel Outcome Study in Suspected Acute Myocardial Infarction | 2027-07 |
| NCT05859620University Hospital, Basel, SwitzerlandImplementation of a Clinical Screening and Response System for Cardiac Complications After Noncardiac Surgery | 2026-12 |
| NCT07780552VASCage GmbHCHIP in Health and Disease | 2027-03 |
| NCT05665608Charite University, Berlin, GermanyPrevention Of Sudden Cardiac Death After Myocardial Infarction by Defibrillator Implantation | 2027-11-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 48 studies in Myocardial Infarction with a site in Austria, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the hypothesis that a fast discharge strategy (discharge at 24 [± 12] hours) following invasive management for acute myocardial infarction is non-inferior to standard of care (>36 hours) with respect to the risk of major adverse cardiovascular events (MACE) during follow-up.
The goal of this randomized, multicenter trial is to assess the safety of a fast discharge strategy following acute myocardial infarction as compared to standard of care. The trial will evaluate the hypothesis that a fast discharge strategy (discharge at 24 [± 12] hours) following invasive management of acute myocardial infarction is non-inferior to standard of care (discharge >36 hours) with respect to the risk of major adverse cardiovascular events at 12 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients undergo a standard post-infarction care, with discharge at \>36 hours after invasive management of acute myocardial infarction.
Fast discharge at 24 (+/-12) hours after invasive management of acute myocardial infarction.
Procedure: Fast discharge strategy
Patients undergoing invasive management after myocardial infarction will be discharged after 24 (+/- 12) hours.
MACE
MACE is defined as a composite of all-cause death, myocardial re-infarction and unscheduled cardiovascular re-hospitalization.
Time frame: From the date of randomization until the first documented event during the follow-up period (up to 12 months).
All cause death
Death from any cause.
Time frame: From the date of randomization until the first documented event during the follow-up period (up to 12 months).
Number of participants with myocardial re-infarction
Number of participants experiencing myocardial re-infarction
Time frame: From the date of randomization until the first documented event during the follow-up period (up to 12 months).
Number of participants with unscheduled cardiovascular re-hospitalization
Number of participants with unscheduled cardiovascular re-hospitalization
Time frame: From the date of randomization until the first documented event during the follow-up period (up to 12 months).
Number of participants with Cardiovascular death
Number of participants experiencing cardiovascular-related death
Time frame: From the date of randomization until the first documented event during the follow-up period (up to 12 months).
Number of participants hospitalized for heart failure
Number of participants hospitalized for heart failure
Time frame: From the date of randomization until the first documented event during the follow-up period (up to 12 months).
Number of participants expiring hospitalization from any cause
Number of participants expiring hospitalization from any cause
Time frame: From the date of randomization until the first documented event during the follow-up period (up to 12 months).
Number of patients experiencing a stroke
Number of patients experiencing a stroke
Time frame: From the date of randomization until the first documented event during the follow-up period (up to 12 months).
Number of participants with a bleeding event
Number of participants with a bleeding event
Time frame: From the date of randomization until the first documented event during the follow-up period (up to 12 months).
Healthcare costs per patient between randomization and 12 months
An economic evaluation will be conducted from the healthcare payer perspective. Direct healthcare costs, including intervention costs, hospitalizations, outpatient visits, diagnostic procedures, and concomitant medications, will be collected prospectively for each participant over the study period. Mean total healthcare costs per patient will be calculated and compared between study groups.
Time frame: From the date of randomization until the first documented event during the follow-up period (up to 12 months).
Length of hospital stay
Number of days in hospital from time of infarction to hospital discharge
Time frame: From the date of randomization to the date of hospital discharge, for up to 100 days
Percentage of patients on guideline-directed therapy
Percentage of patients on guideline-directed therapy
Time frame: From the date of randomization until the first documented event during the follow-up period (up to 12 months).
Infection
Infection leading to hospitalization
Time frame: At 30 days
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2024 (actual). Primary completion is estimated for Dec 2029, 60 months after the start.
Of 322 non-industry interventional studies with no phase under Myocardial Infarction, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 58. This study's planned 60 months is above that.
Counting every sponsor, half of 355 studies reached it within 34 months; a quarter within 15 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University Innsbruck →